Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Allogene Therapeutics (ALLO) Shares Issued (2019 - 2025)

Allogene Therapeutics' Shares Issued history spans 7 years, with the latest figure at -$10.0 million for Q2 2025.

  • For Q2 2025, Shares Issued fell 1330.26% year-over-year to -$10.0 million; the TTM value through Jun 2025 reached $722000.0, down 38.24%, while the annual FY2024 figure was $1.5 million, 26.45% down from the prior year.
  • Shares Issued for Q2 2025 was -$10.0 million at Allogene Therapeutics, down from $10.0 million in the prior quarter.
  • Across five years, Shares Issued topped out at $10.0 million in Q1 2025 and bottomed at -$10.0 million in Q2 2025.
  • The 5-year median for Shares Issued is $757500.0 (2021), against an average of $258714.3.
  • The largest annual shift saw Shares Issued skyrocketed 182.34% in 2021 before it plummeted 1330.26% in 2025.
  • A 5-year view of Shares Issued shows it stood at -$8.0 million in 2021, then surged by 80.93% to -$1.5 million in 2022, then soared by 73.27% to -$409000.0 in 2023, then soared by 276.53% to $722000.0 in 2024, then plummeted by 1485.32% to -$10.0 million in 2025.
  • Per Business Quant, the three most recent readings for ALLO's Shares Issued are -$10.0 million (Q2 2025), $10.0 million (Q1 2025), and $722000.0 (Q3 2024).